Frazer Monica, Swift Caroline, Sargent Andrew, Leszko Michael, Buysman Erin, Gronroos Noelle N, Alvarez Sara, Dunn Tyler J, Noone Josh, Gamble Cory L
QualityMetric, Johnston, RI USA.
Optum, 11000 Optum Circle Eden Prairie, Eden Prairie, MN 55344 USA.
J Diabetes Metab Disord. 2023 Nov 27;23(1):727-737. doi: 10.1007/s40200-023-01341-y. eCollection 2024 Jun.
The purpose of this study was to evaluate patient, prescriber, and dose characteristics and evaluate changes in glycated hemoglobin (HbA) for patients prescribed once weekly semaglutide for diabetes (OW sema T2D).
This study was a retrospective claims-based study using the Optum Research Database. The sample included adult patients who had at least one claim for OW sema T2D between Jan 1, 2018, and Dec 31, 2019, were continuously enrolled in the health plan and had a diagnosis of type 2 diabetes (T2DM) during the pre-index or post-index periods. Demographic and clinical characteristics of patients using OW sema T2D were collected, as were the dose and prescriber specialty and the change between pre-index and post-index HbA measures was calculated. Results were stratified by the latest pre-index HbA measurement (HbA greater than or equal to 9.0%, uncontrolled vs. HbA less than 9%, controlled). Statistical comparisons between HbA groups were conducted.
Most patients, 76.3%, were prescribed a 0.25/0.50 mg dose of OW sema T2D. Patients had an overall decrease in HbA of 0.8% and patients with uncontrolled diabetes had a greater reduction in mean HbA compared to those with controlled diabetes (-2.1% vs. -0.3%, p < 0.001). Most patients had their index dose of OW sema T2D prescribed by endocrinologists (27.6%) primary care providers (24.6%) and internal medicine providers (21.6%).
OW sema T2D is an effective real-world T2DM treatment. Future research should further investigate real-world use patterns of this medication.
本研究的目的是评估患者、处方医生和剂量特征，并评估接受每周一次司美格鲁肽治疗糖尿病（OW司美格鲁肽治疗2型糖尿病）的患者糖化血红蛋白（HbA）的变化。
本研究是一项基于索赔数据的回顾性研究，使用Optum研究数据库。样本包括在2018年1月1日至2019年12月31日期间至少有一次OW司美格鲁肽治疗2型糖尿病索赔记录、持续参加健康计划且在索引前或索引后期间被诊断为2型糖尿病（T2DM）的成年患者。收集了使用OW司美格鲁肽治疗2型糖尿病患者的人口统计学和临床特征、剂量、处方医生专业，并计算了索引前和索引后HbA测量值之间的变化。结果按最新索引前HbA测量值分层（HbA大于或等于9.0%，未控制组与HbA小于9%，控制组）。对HbA组之间进行了统计比较。
大多数患者（76.3%）接受了0.25/0.50mg剂量的OW司美格鲁肽治疗2型糖尿病。患者的HbA总体下降了0.8%，与糖尿病得到控制的患者相比，未控制糖尿病的患者平均HbA下降幅度更大（-2.1%对-0.3%，p＜0.001）。大多数患者的OW司美格鲁肽索引剂量由内分泌科医生（27.6%）、初级保健医生（24.6%）和内科医生（21.6%）开具。
OW司美格鲁肽治疗2型糖尿病是一种有效的现实世界治疗方法。未来的研究应进一步调查这种药物的现实世界使用模式。
